[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3114120T3 - Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere - Google Patents

Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere Download PDF

Info

Publication number
DK3114120T3
DK3114120T3 DK15710686.5T DK15710686T DK3114120T3 DK 3114120 T3 DK3114120 T3 DK 3114120T3 DK 15710686 T DK15710686 T DK 15710686T DK 3114120 T3 DK3114120 T3 DK 3114120T3
Authority
DK
Denmark
Prior art keywords
dihydropyridinon
tetrazolon
substituted
mgat2 inhibitors
mgat2
Prior art date
Application number
DK15710686.5T
Other languages
English (en)
Inventor
Saleem Ahmad
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52686513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3114120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3114120T3 publication Critical patent/DK3114120T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15710686.5T 2014-03-07 2015-03-05 Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere DK3114120T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949490P 2014-03-07 2014-03-07
PCT/US2015/018870 WO2015134699A1 (en) 2014-03-07 2015-03-05 Tetrazolone-substituted dihydropyridinone mgat2 inhibitors

Publications (1)

Publication Number Publication Date
DK3114120T3 true DK3114120T3 (da) 2019-05-20

Family

ID=52686513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15710686.5T DK3114120T3 (da) 2014-03-07 2015-03-05 Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere

Country Status (31)

Country Link
US (6) US9688656B2 (da)
EP (1) EP3114120B1 (da)
JP (1) JP6449919B2 (da)
KR (1) KR102336371B1 (da)
CN (1) CN106061968B (da)
AU (1) AU2015227140B2 (da)
BR (1) BR112016019487B1 (da)
CA (1) CA2941951C (da)
CL (1) CL2016002238A1 (da)
CY (1) CY1121746T1 (da)
DK (1) DK3114120T3 (da)
EA (1) EA030561B1 (da)
ES (1) ES2719713T3 (da)
HR (1) HRP20190668T1 (da)
HU (1) HUE044272T2 (da)
IL (1) IL247592B (da)
LT (1) LT3114120T (da)
MA (1) MA39335B1 (da)
MX (1) MX2016011223A (da)
MY (1) MY176921A (da)
NZ (1) NZ724890A (da)
PE (1) PE20161369A1 (da)
PH (1) PH12016501517B1 (da)
PL (1) PL3114120T3 (da)
PT (1) PT3114120T (da)
RS (1) RS58740B1 (da)
SG (1) SG11201607393XA (da)
SI (1) SI3114120T1 (da)
TR (1) TR201906325T4 (da)
WO (1) WO2015134699A1 (da)
ZA (1) ZA201606174B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
AU2015227140B2 (en) 2014-03-07 2019-01-24 Bristol-Myers Squibb Company Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors
EP3154944B1 (en) 2014-06-11 2018-03-14 Bristol-Myers Squibb Company Substituted pyridinones as mgat2 inhibitors
CN105218518B (zh) * 2015-09-15 2018-01-12 青岛科标检测研究院有限公司 一种可用于制备供热采暖系统清洗剂的化合物及其制备方法
WO2017069224A1 (ja) * 2015-10-22 2017-04-27 塩野義製薬株式会社 Mgat2阻害活性を有するスピロ環誘導体
WO2017110841A1 (ja) * 2015-12-21 2017-06-29 塩野義製薬株式会社 Mgat2阻害活性を有する非芳香族複素環誘導体
JP2020158390A (ja) * 2017-06-20 2020-10-01 塩野義製薬株式会社 Mgat2阻害活性を有する非芳香族複素環誘導体およびそれらを含有する医薬組成物
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
TWI840489B (zh) * 2019-01-11 2024-05-01 日商鹽野義製藥股份有限公司 酮衍生物
JPWO2023038039A1 (da) * 2021-09-08 2023-03-16
EP4201923A1 (en) 2021-12-23 2023-06-28 Karl-Franzens-Universität Graz 5-substituted 2,3-dihydropyridin-4-ones and process for preparing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US20100016365A1 (en) 2008-07-17 2010-01-21 Auspex Pharmaceuticals, Inc. Substituted 4-amino-piperidines
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
EP3004059B1 (en) 2013-05-29 2017-09-20 Bristol-Myers Squibb Company Dihydropyridinone mgat2 inhibitors
MX2016011105A (es) 2014-03-07 2016-12-12 Bristol Myers Squibb Co Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
AU2015227140B2 (en) * 2014-03-07 2019-01-24 Bristol-Myers Squibb Company Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors

Also Published As

Publication number Publication date
ZA201606174B (en) 2018-05-30
US10093650B2 (en) 2018-10-09
NZ724890A (en) 2019-11-29
PL3114120T3 (pl) 2019-08-30
CL2016002238A1 (es) 2017-03-03
BR112016019487B1 (pt) 2023-01-17
US20180127394A1 (en) 2018-05-10
HRP20190668T1 (hr) 2019-06-14
BR112016019487A2 (da) 2017-08-15
MX2016011223A (es) 2016-11-30
US9688656B2 (en) 2017-06-27
PH12016501517A1 (en) 2017-02-06
US20180370945A1 (en) 2018-12-27
JP2017508794A (ja) 2017-03-30
ES2719713T3 (es) 2019-07-12
US10538505B2 (en) 2020-01-21
MY176921A (en) 2020-08-26
LT3114120T (lt) 2019-05-10
IL247592B (en) 2018-12-31
PT3114120T (pt) 2019-05-08
US11479538B2 (en) 2022-10-25
CA2941951A1 (en) 2015-09-11
HUE044272T2 (hu) 2019-10-28
KR102336371B1 (ko) 2021-12-06
EA201691670A1 (ru) 2016-12-30
EA030561B1 (ru) 2018-08-31
MA39335A1 (fr) 2017-09-29
CY1121746T1 (el) 2020-07-31
AU2015227140B2 (en) 2019-01-24
US9896431B2 (en) 2018-02-20
PH12016501517B1 (en) 2017-02-06
EP3114120A1 (en) 2017-01-11
WO2015134699A1 (en) 2015-09-11
US20170015648A1 (en) 2017-01-19
CA2941951C (en) 2021-11-16
RS58740B1 (sr) 2019-06-28
TR201906325T4 (tr) 2019-05-21
US20190263776A1 (en) 2019-08-29
JP6449919B2 (ja) 2019-01-09
MA39335B1 (fr) 2019-12-31
SI3114120T1 (sl) 2019-04-30
CN106061968A (zh) 2016-10-26
US10329273B2 (en) 2019-06-25
US20170260159A1 (en) 2017-09-14
CN106061968B (zh) 2020-03-27
EP3114120B1 (en) 2019-02-13
SG11201607393XA (en) 2016-10-28
US20200095221A1 (en) 2020-03-26
AU2015227140A1 (en) 2016-10-20
KR20160120789A (ko) 2016-10-18
PE20161369A1 (es) 2016-12-17

Similar Documents

Publication Publication Date Title
DK3442972T3 (da) Bromdomænehæmmere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3006072T3 (da) Karadgang
DK3119396T3 (da) Muscarinreceptoragonister
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DE112015001664A5 (de) Betätigungsaktuator
DK3183340T3 (da) Termolabile exonukleaser
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DK3091875T3 (da) Vipbar taburet